Glaxosmithkline Pharmaceuticals Ltd vs Vivimed Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2437 as of 11 May 13:02 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Vivimed Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Vivimed Labs Ltd changed from ₹ 131.42 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Vivimed Labs Ltd for the Dec '25 is ₹ 15.99 crore as compare to the Sep '25 revenue of ₹ 20.82 crore. This represent the decline of -23.2% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Vivimed Labs Ltd for the Dec '25 is ₹ -10.92 crore as compare to the Sep '25 ebitda of ₹ -0.74 crore. This represent the growth of 1375% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Vivimed Labs Ltd changed from ₹ -15.25 crore to ₹ -16.55 crore over 7 quarters. This represents a CAGR of 4.79% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Vivimed Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Vivimed Labs Ltd

Vivimed Labs Limited was originally incorporated on September 22, 1988 as a private limited company in the name of Emgi Pharmaceuticals & Chemicals Pvt Ltd. On April 21, 1994, the company got converted into a public limited company and the name was changed to Emgi Pharmaceuticals & Chemicals Ltd and thereafter, the Company name was finally changed to Vivimed Labs Limited on April 22, 1997. The Company is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations.
The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing.
The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Vivimed Labs Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Vivimed Labs Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 42,092 Cr while Market cap of Vivimed Labs Ltd is 57 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Vivimed Labs Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Vivimed Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Vivimed Labs Ltd?

As of May 11, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2484.7. On the other hand, Vivimed Labs Ltd stock price is INR ₹6.88.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Vivimed Labs Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Vivimed Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.